Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison

Semaglutide, tirzepatide, and retatrutide are three of the most-referenced peptides in modern metabolic research. The cleanest way to understand how they differ is by counting receptors: semaglutide engages one, tirzepatide engages two, and retatrutide engages three. Each step up adds another signaling pathway for researchers to characterize.

Semaglutide — single agonist (GLP-1)

Semaglutide is a GLP-1 receptor agonist — an acylated analogue of glucagon-like peptide-1. Research has examined its effects on glycemic regulation, gastric motility, and insulin receptor signaling pathways in vitro. It is the most widely referenced peptide in this class and is often the baseline that newer molecules are compared against.

Tirzepatide — dual agonist (GIP + GLP-1)

Tirzepatide adds a second receptor: it is a dual agonist of both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Research demonstrates modulation of glycemic signaling and adipose tissue regulation in preclinical models, with the second incretin pathway (GIP) being the key addition over a single GLP-1 agonist.

Retatrutide — triple agonist (GIP + GLP-1 + glucagon)

Retatrutide adds a third receptor on top of the two that tirzepatide targets: the glucagon receptor. This third pathway is associated in preclinical literature with energy expenditure and hepatic lipid handling. Research describes differential receptor activation profiles compared with dual agonists — meaning the relative potency at each receptor matters, not just the count.

Side-by-side summary

• Semaglutide — 1 receptor: GLP-1
• Tirzepatide — 2 receptors: GIP + GLP-1
• Retatrutide — 3 receptors: GIP + GLP-1 + glucagon
• Across the series, each addition introduces a new signaling pathway studied in metabolic research

Keep reading